In summary, our data indicate that JPYS can correct CKD anemia through induction of EPO production and regulation of iron metabolic targets and the mechanism of which involves in the translational control of HIF-2α protein accumulation via ERK signaling. The gene discussed is EPO; the disease is chronic kidney disease.